---
title: "New England Journal of Medicine Retracts Amgen Drug Trial Paper Amid Data Integrity Concerns"
url: https://www.herenovi.com/2026/06/30/new-england-journal-medicine-retracts-amgen/
date: 2026-06-30T11:18:09-04:00
modified: 2026-06-30T11:18:09-04:00
author: "Ramona Cordero"
categories: ["Health"]
site: "HERE Novi"
attribution: "HERE Novi"
---

# New England Journal of Medicine Retracts Amgen Drug Trial Paper Amid Data Integrity Concerns

*Source: [HERE Novi](https://www.herenovi.com/2026/06/30/new-england-journal-medicine-retracts-amgen/) — June 30, 2026 by Ramona Cordero*

The New England Journal of Medicine (NEJM) has retracted a significant clinical trial paper that provided evidence for Amgen’s drug Tavneos. The retraction follows concerns raised about the integrity of the patient outcome data and allegations that some researchers involved in the study were unblinded.

The paper, which played a role in the drug’s supportive evidence, was scrutinized for potential alterations to patient data. Additionally, reports indicated that the protocol for blinding researchers to treatment assignments may have been breached. These issues collectively led the NEJM to withdraw the publication.

Tavneos is a medication used in the treatment of certain autoimmune conditions. The drug’s efficacy and safety profile were, in part, established by the now-retracted study. The retraction raises questions about the foundational data upon which the drug’s clinical support was built.

Drug trial integrity is a critical component of medical research and regulatory approval. When data is called into question, it can have far-reaching implications for patient care, physician prescribing habits, and the pharmaceutical industry. The NEJM’s decision to retract the paper underscores the journal’s commitment to upholding scientific standards and ensuring the reliability of published research.

This development highlights the rigorous oversight required in pharmaceutical research. Independent verification of trial data and adherence to blinding protocols are essential to prevent bias and ensure that treatment decisions are based on accurate and unbiased information. The scientific community will likely be examining the implications of this retraction for similar studies and for the broader understanding of Tavneos’s clinical utility.

Amgen has not yet issued a public statement regarding the retraction. The company’s response and any further investigations into the trial data will be closely watched by stakeholders in the medical and pharmaceutical fields.

Why it matters in Novi:

Patients in Novi and the surrounding Oakland County region who may be prescribed Tavneos or are participating in clinical trials for similar medications rely on the integrity of published medical research. The retraction of this pivotal trial paper by the New England Journal of Medicine underscores the importance of data verification in drug development. For healthcare providers at institutions like Providence Park Hospital, understanding the full context of a drug’s supporting evidence, including any retractions or data concerns, is crucial for informed patient care and treatment decisions. This event serves as a reminder of the ongoing need for transparency and accuracy in medical science, impacting how physicians in Novi approach treatment protocols for rare diseases.